Successful radical surgical resection of initially unresectable intrahepatic cholangiocarcinoma by downsizing chemotherapy with gemcitabine plus cisplatin: a case report

Ryosuke Takayanagi\textsuperscript{1}, Shigetsugu Takano\textsuperscript{1*}, Kensuke Sugiura\textsuperscript{1}, Hideyuki Yoshitomi\textsuperscript{1}, Katsunori Furukawa\textsuperscript{1}, Tsukasa Takayashiki\textsuperscript{1}, Satoshi Kuboki\textsuperscript{1}, Atsushi Kato\textsuperscript{2}, Masaru Miyazaki\textsuperscript{1,2} and Masayuki Ohtsuka\textsuperscript{1}

Abstract

Background: Intrahepatic cholangiocarcinoma (ICC) is a subtype of biliary tract cancer (BTC). Recently, downsizing chemotherapy has been applied to initially unresectable BTCs, including ICC.

Case presentation: We report a case of liver resection in a 23-year-old woman who was diagnosed with initially unresectable ICC attached to the inferior vena cava, with portal vein (PV) cavernous transformation. Positron emission tomography (PET) showed fluorodeoxyglucose (FDG) uptake in the para-aortic lymph nodes. Upon using downsizing chemotherapy (the combination of gemcitabine [GEM] and cisplatin [CDDP]), the size of tumor reduced by 55% and FDG uptake in the para-aortic lymph node metastases disappeared. A right hemihepatectomy was performed, along with dissection of lymph nodes, including the para-aortic lymph nodes. The PV cavernous transformation was preserved to maintain collateral flow as much as possible, as it was considered to originate from a congenital anomaly. Pathological examination revealed that R0 resection was performed and that there were no viable neoplastic cells remaining in the para-aortic lymph nodes. The patient is alive at 31 months after initial treatment, with a local recurrence.

Conclusion: Downsizing chemotherapy with GEM plus CDDP followed by radical surgical resection is an attractive treatment for initially unresectable BTC.

Keywords: Intrahepatic cholangiocarcinoma (ICC), Biliary tract cancer (BTC), Initially unresectable BTC, Downsizing chemotherapy, Conversion surgery

Background

Intrahepatic cholangiocarcinoma (ICC), a form of biliary tract cancer (BTC), is an uncommon cancer arising from the epithelium of the intrahepatic bile duct. Surgical resection is the only curative treatment option that leads to long-term survival in BTC patients. However, the majority of patients are initially diagnosed with unresectable tumors due to locally advanced or metastatic disease. Recently, systemic chemotherapy has been utilized, and some initially unresectable BTCs can become resectable following downsizing chemotherapy. Herein, we describe a case of successful radical surgical resection following downsizing chemotherapy for initially unresectable advanced ICC.

Case presentation

A 23-year-old woman with no relevant past medical or surgical history was referred from a local hospital after complaining of right upper quadrant pain for several weeks. On physical examination, right upper quadrant
tenderness was the only abnormal finding during the first visit. Initial laboratory findings were also unremarkable, except for a high level of carbohydrate antigen 19-9 (CA19-9; 20,300 U/ml). Abdominal computed tomography (CT) and magnetic resonance imaging (MRI) revealed focal dilation of the right intrahepatic bile duct and a low contrast effect tumor measuring 42 mm in hepatic segments 1 and 8; ICC was suspected (Fig. 1a, b). The tumor was attached to the inferior vena cava (IVC) and had invaded the right portal vein (PV) leading to cavernous transformation instead of canonical PV. Positron emission tomography (PET) showed fluorodeoxyglucose (FDG) uptake in the primary liver tumor and para-aortic lymph nodes (Fig. 1c).

We consider the cases those in which surgical resection could not be achieved even by aggressive surgical procedures, including combined vascular resection as unresectable ICCs. On the basis of these findings, the patient was diagnosed with initially unresectable ICC with para-aortic lymph node metastasis and subsequently treated with a combined chemotherapy regimen of gemcitabine (GEM 1000 mg/m²) and cisplatin (CDDP 25 mg/m²). This combination was intravenously administered on days 1 and 8 and was repeated every 3 weeks under a downsizing regimen.

After eight courses of combination chemotherapy over 5 months, CT, MRI, and PET imaging demonstrated an effective response to chemotherapy. The size of the primary tumor had decreased to 18 mm (55% reduction), and the tumor was no longer attached to the IVC (Fig. 1d, e). FDG uptake in the para-aortic lymph nodes almost disappeared (Fig. 1f), and the level of CA19-9 decreased to 738 U/ml (Fig. 2). The effect of downsizing chemotherapy was partial response (PR) in RECIST criteria. The TNM staging of pre- and post-chemotherapy were T3N1M1 stage IVb and T1N0M0 stage I in UICC criteria, respectively. Nevertheless, the PV cavernous transformation did not improve. We thus concluded that this PV cavernous transformation had originated from a congenital anomaly (Fig. 3a). After discussion with the patient and her family, we decided to perform radical surgical resection to achieve the cure of disease. Right hemihepatectomy and dissection of lymph nodes, including the para-aortic lymph nodes, were performed. During right PV resection, the PV cavernous transformation was preserved to maintain collateral flow through the PV as much as possible (Fig. 3b). The margins of the right bile duct showed no evidence of malignancy during intraoperative frozen section analysis.

Microscopic pathological examination showed that R0 (no residual tumor) resection had been successful and that more than 50% of the tumor cells had been replaced with fibrosis (Evans’ criteria IIb) (Fig. 4a, b). No viable tumor cells were visible in the para-aortic lymph nodes that showed FDG uptake in the initial PET scan. However, there was slight extracapsular invasion in the para-aortic nerve (Fig. 4c). According to the pathological findings (well differentiated tubular adenocarcinoma, pT3, pN0, pM1 (OTH, para-aortic nerve)), UICC stage of this patient was defined as stage IVb. The patient suffered from bile duct stricture as a postoperative complication. After re-suturing of the stump of the bile
duct with enough patency in reoperation, the patient made a satisfactory recovery and was discharged on postoperative day 11. The patient is alive 31 months after the initial treatment (24 months after operation) with a local tumor recurrence.

Discussion
In surgical resection for ICC, R0 resection is one of the most favorable prognostic factors [1, 2]. The prognosis of R1 and R2 (microscopic and macroscopic residual tumor) resection is comparable to the prognosis of patients who do not undergo surgical resection and those who receive only palliative treatment [3]. Furthermore, the number of lymph node metastases is another important prognostic factor in ICC. Patients with more than three lymph nodes metastases have more unfavorable outcomes than patients with one or two lymph node metastases (3-year survival: 0 vs. 50%, respectively) [3].

Many patients are diagnosed initially with unresectable tumors due to locally advanced or metastatic disease, silent clinical symptoms, involvement of blood vessels, extension into both hepatic lobes, or rapid disease progression [4]. The optimal treatment for patients with locally advanced unresectable or metastatic disease is yet to be determined. Recently, systemic chemotherapy has contributed to improvements in overall survival. In the UK, a phase III randomized controlled trial demonstrated that the median survival time (MST) of overall survival (OS) with GEM plus CDDP combination therapy was significantly improved compared to that with gemcitabine alone (11.7 vs. 8.3 months, respectively, \( p < 0.001 \)) [5]. For unresectable BTC, GEM plus CDDP combination therapy is recommended as a standard therapy.

A previous report looked at the effectiveness of downsizing chemotherapy (distinguished from neoadjuvant chemotherapy) and subsequent so-called “conversion surgery” for initially unresectable BTC [6]. We also recently reported that in 10 of 39 (25.6%) locally advanced unresectable BTC patients, the size of the tumor was reduced by downsizing chemotherapy, and conversion surgery was successfully performed as a result. Additionally, this downsizing chemotherapy and conversion surgery strategy led to longer survival than that with chemotherapy alone (MST: 17.9 months for chemotherapy plus surgical resection vs. 12.4 months for chemotherapy alone) [7]. Although there is a certain bias in patient selection, this could represent a promising treatment for initially unresectable locally advanced BTC.

The efficacy of neoadjuvant chemotherapy against potentially resectable BTC is uncertain. A previous report indicated that neoadjuvant therapy can improve survival by controlling regional extension [8]. Contrary to this, another report suggested that neoadjuvant chemotherapy decreased the survival rate compared to that on immediate resection [9]. Prospective studies are needed to establish neoadjuvant chemotherapy as a treatment for potentially resectable BTC.

PV cavernous transformation is the angiographic appearance of numerous collateral vessels around the PV owing to various reasons. These are classified as idiopathic causes (e.g., congenital malformation, or following hepatobiliary surgery) or secondary causes (e.g., liver cirrhosis, thrombosis, tumor) [10]. In this case, there were no hepatofugal collateral pathways caused by splenomegaly, a gastric or esophageal varix, or any hepatopetal collateral pathways. Furthermore, intraoperative findings
suggested that the cavernous transformation was due to a congenital etiology, as the obstruction site was distant from the tumor and was soft under palpation. Unfortunately there is no previous CT or portography, however, it is speculated that the etiology of congenital PV cavernous transformation may result from portal vein malformation, or portal thrombosis for omphalitis or pylephlebitis.

Until October 2016, we experienced 15 cases of surgical resection for initially unresectable BTCs including this case. The periods of downsizing chemotherapy to surgical resection were varied; 22.7 ± 11.1 weeks (mean ± standard deviation). Among all 15 patients, N0 (no lymph node metastasis) was pathologically diagnosed for 9 patients and N1 (positive for lymph node metastasis) for 6 patients, and R0 resection was performed for 12 patients and R1 resection for 3 patients, respectively. According to Kaplan-Meier method, the MST of OS was calculated and log-lank test was used to test for significant differences between N0 and N1 group, and between R0 and R1 group. The MST of OS in N0 group (34.3 months) was significantly longer compared with that in N1 group (12.4 months) (p = 0.031). The MST of OS in R0 group was also significantly longer than that in R1 group (30.9 months for R0 group vs. 4.1 months for R1 group, p = 0.012). Although the number of cases is limited, these results implicated that N0 and R0 resection are important favorable prognostic factors for unresectable BTC patients who have undergone surgery after downsizing chemotherapy.

Conclusions
We describe a case of successful surgical resection of initially unresectable ICC in a patient with PV cavernous transformation with suspected congenital origin. The combination of GEM and CDDP chemotherapy decreased tumor size and the viability of para-aortic lymph node metastases, enabling surgical resection to be performed. Downsizing chemotherapy with GEM plus CDDP may become an attractive treatment strategy for initially unresectable BTC. Further evidence and prospective studies are required to establish the optimal strategy for treatment of initially unresectable BTC.

Abbreviations
BTC: Biliary tract cancer; CA19-9: Carbohydrate antigen 19-9; CDDP: Cisplatin; CT: Computed tomography; FDG: Fluorodeoxyglucose; GEM: Gemcitabine; ICC: Intrahepatic cholangiocarcinoma; IVC: Inferior vena cava; MRI: Magnetic resonance imaging; MST: Median survival time; OS: Overall survival; PET: Positron emission tomography; PV: Portal vein

Acknowledgements
We thank Dr. Nojima for helpful assistant for 3D image processing.

Funding
The authors received no financial support for the preparation of this case report.

Authors’ contributions
RT and ST gathered the patient’s data and wrote the manuscript. ST treated the patient with downsizing and adjuvant chemotherapy. ST, AK, and MM participated in the surgery. KS and MO were responsible for pathological diagnosis of this case. ST, KS, HY, KF, TT, SK, MM, and MO discussed the data with RT and helped write the manuscript. All authors approved the final manuscript.

Consent for publication
Written informed consent was obtained from the patient for publication of this case report and any accompanying images.
Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of General Surgery, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8677, Japan. 2Department of Gastroenterological Surgery, Mita Hospital, International University of Health and Welfare, Tokyo, Japan.

Received: 13 September 2017 Accepted: 15 November 2017
Published online: 21 November 2017

References
1. Miwa S, Miyagawa S, Kobayasi A, et al. Predictive factors for intrahepatic cholangiocarcinoma recurrence in the liver following surgery. J Gastroenterol. 2006;41:893–900.
2. Nakagawa T, Kamiyama T, Kusaochi N, et al. Number of lymph node metastases is a significant prognostic factor in intrahepatic cholangiocarcinoma. World J Surg. 2005;29:728–33.
3. Witzmann H, Herr F, Ringel U, et al. Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to r1/r2 resection. Ann Surg. 2006;244:230–9.
4. Miyakawa S, Ishihara S, Horiguchi A, et al. Biliary tract cancer treatment: 5584 result from the biliary tract cancer statistics registry from 1998 to 2004 in japan. J Hepato-Biliary-Pancreat Surg. 2009;16:1–7.
5. Vallee J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–81.
6. Kato A, Shimizu H, Ohtsuka M, et al. Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer: a retrospective single-center study. Ann Surg Oncol. 2013;20:318–24.
7. Kato A, Shimizu H, Ohtsuka M, et al. Downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer patients treated with gemcitabine plus cisplatin combination therapy followed by radical surgery. Ann Surg Oncol. 2015;22:s1093–9.
8. Kobayashi S, Tomokuni A, Gotoh K, et al. Evaluation of the safety and pathological effects of neoadjuvant full-dose gemcitabine combination radiation therapy in patients with biliary tract cancer. Cancer Chemother Pharmacol. 2015;76(6):1191–8.
9. Glazer ES, Liu P, Abdalla EK, et al. Neither neoadjuvant nor adjuvant therapy increases survival after biliary tract cancer resection with wide negative margins. J Gastrointest Surg. 2012;16:1666–71.
10. De Gaetano AM, Lafotune M, Patriquin H, et al. Cavernous transformation of the portal vein: patterns of intrahepatic and splanchic collateral circulation detected with Doppler sonography. Am J Roentgenol. 1995;165:1151–5.